131 related articles for article (PubMed ID: 32162977)
1. Systematic literature review of the global burden of illness of mantle cell lymphoma.
Monga N; Garside J; Quigley J; Hudson M; O'Donovan P; O'Rourke J; Tapprich C; Parisi L; Davids MS; Tam C
Curr Med Res Opin; 2020 May; 36(5):843-852. PubMed ID: 32162977
[No Abstract] [Full Text] [Related]
2. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Kabadi SM; Near A; Wada K; Burudpakdee C
Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
[TBL] [Abstract][Full Text] [Related]
3. Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma.
Monga N; Garside J; Davids MS; Tam C; Ward K; Fotheringham I; O'Donovan P; Parisi L; Tapprich C
Pharmacoecon Open; 2021 Jun; 5(2):175-186. PubMed ID: 32996067
[TBL] [Abstract][Full Text] [Related]
4. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States.
Goyal RK; Nagar SP; Kabadi SM; Kaye JA; Seal B; Mato AR
Leuk Lymphoma; 2019 Apr; 60(4):955-963. PubMed ID: 30277099
[TBL] [Abstract][Full Text] [Related]
5. Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada.
Anglin P; Elia-Pacitti J; Eberg M; Muratov S; Kukaswadia A; Sharma A; Ewara EM
Curr Oncol; 2023 Jun; 30(6):5529-5545. PubMed ID: 37366901
[TBL] [Abstract][Full Text] [Related]
6. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs.
Squires P; Puckett J; Ryland KE; Kamal-Bahl S; Raut M; Doshi JA; Huntington SF
Leuk Lymphoma; 2023; 64(11):1752-1770. PubMed ID: 37497877
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma epidemiology: a population-based study in France.
Leux C; Maynadié M; Troussard X; Cabrera Q; Herry A; Le Guyader-Peyrou S; Le Gouill S; Monnereau A
Ann Hematol; 2014 Aug; 93(8):1327-33. PubMed ID: 24763513
[TBL] [Abstract][Full Text] [Related]
9. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Kabadi SM; Byfield SD; LE L; Olufade T
Anticancer Res; 2021 Feb; 41(2):927-936. PubMed ID: 33517299
[TBL] [Abstract][Full Text] [Related]
11. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.
Zhou Y; Wang H; Fang W; Romaguer JE; Zhang Y; Delasalle KB; Kwak L; Yi Q; Du XL; Wang M
Cancer; 2008 Aug; 113(4):791-8. PubMed ID: 18615506
[TBL] [Abstract][Full Text] [Related]
12. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
Cohen JB; Han X; Jemal A; Ward EM; Flowers CR
Cancer; 2016 Aug; 122(15):2356-63. PubMed ID: 27153197
[TBL] [Abstract][Full Text] [Related]
13. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
14. Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.
Augustin A; Le Gouill S; Gressin R; Bertaut A; Monnereau A; Woronoff AS; Trétarre B; Delafosse P; Troussard X; Moreau A; Hermine O; Maynadié M
J Cancer Res Clin Oncol; 2018 Apr; 144(4):629-635. PubMed ID: 29022078
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review.
Njue A; Colosia A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):1-12.e7. PubMed ID: 25052050
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
Hess G; Rule S; Jurczak W; Jerkeman M; Santucci Silva R; Rusconi C; Caballero D; Joao C; Witzens-Harig M; Bence-Bruckler I; Cho SG; Zhou W; Goldberg JD; Trambitas C; Enny C; Vermeulen J; Traina S; Chiou CF; Diels J; Dreyling M
Leuk Lymphoma; 2017 Dec; 58(12):2824-2832. PubMed ID: 28556689
[TBL] [Abstract][Full Text] [Related]
17. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
18. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
Fayad L; Thomas D; Romaguera J
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
20. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.
Yoon DH; Cao J; Chen TY; Izutsu K; Kim SJ; Kwong YL; Lin TY; Thye LS; Xu B; Yang DH; Kim WS
J Hematol Oncol; 2020 Mar; 13(1):21. PubMed ID: 32183871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
